Taysha Gene Therapies Number of Employees 2020-2024 | TSHA

Taysha Gene Therapies number of employees from 2020 to 2024. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
Taysha Gene Therapies Annual Employee Count
2023 52
2022 65
2021 178
2020 38
2019 10
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.336B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.441B 7.12
Dr Reddy's Laboratories (RDY) India $11.160B 21.29
BridgeBio Pharma (BBIO) United States $6.858B 0.00
Bausch Health Cos (BHC) Canada $2.354B 1.71
Supernus Pharmaceuticals (SUPN) United States $1.851B 25.20
Amphastar Pharmaceuticals (AMPH) United States $1.501B 9.02
Personalis (PSNL) United States $0.412B 0.00
Assembly Biosciences (ASMB) United States $0.081B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.008B 0.00
Teligent (TLGT) United States $0.000B 0.00